fda warning letter compounding semaglutide news Beyond the Headlines: Letters to GLP-1 Compounders Guest Letter: Concerns About Compounded

10.1080/02699052.2019.1587000 Summary Keywords stroke, GLP-1, GLP-1R agonists, neuroprotection, diabetes Citation Yang X, Qiang Q, Li N, Feng P, Wei W and Hlscher C (2022) Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research

On the GLP-1 front specifically, the FDA received hundreds of reports from patients who accidentally injected 5 to 20 times their intended dose because of concentration differences in compounded formulations

The NHS and NICE recommend PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) as first-line treatment, alongside lifestyle modifications and management of underlying conditions

doi: 10.1007/BF01645140

HCC Preliminary evidence suggests that GLP-1RAs may provide protective effects against HCC development